Autoimmune Disease Diagnostics Market Size, Report, 2032
Meticulous Research®—a
leading global market research company, published a research report
titled, Autoimmune Disease Diagnostics Market Size, Share, Forecast,
& Trends Analysis By Product (Reagents, Kits, Assays, Instruments), Test
Type (ANA, CRP, ESR, Rheumatoid Factor, Routine Test), Disease Type (Systemic,
Localized) - Global Forecast to 2031.’
According to this
latest publication from Meticulous Research®, the autoimmune disease
diagnostics market is expected to reach $11.45
billion by 2032, at a CAGR of 7.5% during the forecast period. The increasing prevalence of autoimmune
disorders, the growing emphasis on early diagnosis, and the rising awareness
regarding autoimmune diseases are some of the factors driving the growth of
this market.
However, difficulties
in diagnosing autoimmune diseases restrain the growth of this market. Emerging
economies and increasing investments & funding in the autoimmune disease
diagnostics space are expected to generate growth opportunities for the players
in this market. Moreover, the unfavorable reimbursement scenario and high rate
of delayed diagnosis or misdiagnosis are major challenges for market growth.
Key Players
The key players
operating in the autoimmune disease diagnostics market are Thermo Fisher
Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter,
Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson, and Company (U.S.),
PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens
Healthineers AG (Germany), Grifols, S.A. (Spain), and Creative Diagnostics
(U.S.).
Autoimmune Disease
Diagnostics Market: Future Outlook
The autoimmune disease
diagnostics market is segmented based on product, test type, disease type, end
user, and geography. The study also evaluates industry competitors and analyzes
the market at the country level.
Based on product
type, the autoimmune disease
diagnostics market is segmented into reagents, assays & kits; software
& services; and instruments. In 2024, the reagents, assays, & kits
segment is expected to account for the largest share of 84.0% of
the autoimmune disease diagnostics market. The large market share of this
segment is attributed to factors such as the recurrent use of reagents &
kits, the availability of antibodies and other reagents for several test
applications, and the increasing number of launches & approvals.
Based on test type, the autoimmune disease diagnostics market is
segmented into antinuclear antibodies (ANA), C-reactive protein (CRP),
erythrocyte sedimentation rate (ESR), rheumatoid factor, immunoglobulins,
routine blood tests, and other test types. In 2024, the antinuclear antibodies
(ANA) segment is expected to account for the largest share of 29.4% of
the autoimmune disease diagnostics market. The large share of this segment is
attributed to factors such as the high prevalence of autoimmune diseases, the
high accuracy & simplicity of the ANA test for autoimmune disease testing,
and the need for early disease diagnosis to prevent morbidity & mortality.
Based on disease
type, the autoimmune
disease diagnostics market is segmented into systemic autoimmune diseases and
organ-specific autoimmune diseases. In 2024, the systemic autoimmune diseases
segment is expected to account for the larger share of the autoimmune disease
diagnostics market. The large market share of this segment is attributed to the
high prevalence of systemic autoimmune diseases such as multiple sclerosis,
Type-1 diabetes, and systemic lupus erythematosus.
Based on end user, autoimmune disease diagnostics is segmented
into diagnostic laboratories, hospitals & clinics, and academic &
research institutes. In 2024, the hospitals segment is expected to account for
the largest share of the autoimmune disease diagnostics market. The large
market share of this segment is attributed to the high volume of tests
performed in hospitals & clinics and the high demand for early autoimmune
disease diagnosis and treatment.
Geographical Review
This research report
analyzes major geographies and provides a comprehensive analysis of the market
in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy,
Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of
Asia-Pacific), Latin America, and the Middle East & Africa. In 2024, North
America is expected to account for the largest share of 39.6% of
the autoimmune disease diagnostics market, followed by Europe and Asia-Pacific.
North America’s major market share is attributed to factors such as high
healthcare expenditure, high prevalence of autoimmune diseases, increased
awareness among patients regarding autoimmune diseases, and increased funding
and investments towards R&D of autoimmune diseases.
Download Sample
Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5405
Key questions
answered in the report:
- Which are the high-growth market segments
in terms of product, test type, disease type, end user, and
region/country?
- What was the historical market size for
autoimmune disease diagnostics across the globe?
- What are the market forecasts and
estimates for 2024–2031?
- What are the major drivers, restraints,
opportunities, and challenges in the global autoimmune disease diagnostics
market?
- Who are the major players in the
autoimmune disease diagnostics market?
- How is the competitive landscape, and who
are the market leaders in the global autoimmune disease diagnostics
market?
- What are the recent developments in the
global autoimmune disease diagnostics market?
- What strategies are adopted by the major
players in the global autoimmune disease diagnostics market?
- What are the geographical trends and
high-growth regions/countries?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment